Original from: genomeweb
BGI Genomics said on Friday that its multiplexed test for SARS-CoV-2, influenza A, and influenza B is now included in the Australian Register of Therapeutic Goods.
The Chinese genomics company, based in Shenzhen, said the real-time fluorescent RT-PCR test was developed for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples in a single reaction.
The designation clears the assay’s entrance to the Australian market, accelerating the company’s rapid growth in the international market, BGI Genomics said in a statement.
BGI Genomics previously received CE marking for two multiplexed tests for SARS-CoV-2 and influenza A/B manufactured by its subsidiary BGI PathoGenesis Pharmaceutical Technology in September 2020.
Source: BGI Genomics Gets Australian Regulatory Approval for Multiplexed SARS-CoV-2, Influenza Test
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.